NALMEFENE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H25NO3
Molecular Weight	339.4281
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6

InChI

InChIKey=WJBLNOPPDWQMCH-MBPVOVBZSA-N

InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26810044 | https://www.ncbi.nlm.nih.gov/pubmed/25187751 | https://www.ncbi.nlm.nih.gov/pubmed/25302021 | https://www.medicines.org.uk/emc/medicine/27609

Nalmefene is the first medication approved for alcoholism with the primary goal of reducing alcohol intake in an as needed approach. Nalmefene received a marketing authorization valid throughout the European Union on February 25, 2013 and is under development in Asia. Nalmefene is an opioid system modulator with a distinct μ, δ, and κ receptor profile. In vitro studies have demonstrated that Nalmefene is a selective opioid receptor ligand with antagonist activity at the μ and δ receptors and partial agonist activity at the κ receptor. In vivo studies have demonstrated that nalmefene reduces alcohol consumption, possibly by modulating cortico-mesolimbic functions. In the US, immediate-release injectable nalmefene was approved in 1995 as an antidote for opioid overdose. It was sold under the trade name Revex. The product was discontinued by its manufacturer around 2008. Currently Nalmefene is sold under the trade name Selincro. Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level, without physical withdrawal symptoms and who do not require immediate detoxification.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Opioid receptors; mu/kappa/delta 33 Target ID: CHEMBL2095181 Sources: http://ec.europa.eu/health/documents/community-register/2013/20130225125325/anx_125325_en.pdf \| https://www.medicines.org.uk/emc/medicine/27609#PHARMACOLOGICAL_PROPS	Antagonist 2849
Mu opioid receptor 231 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19027293 \| http://ec.europa.eu/health/documents/community-register/2013/20130225125325/anx_125325_en.pdf	Antagonist 2849	0.44 nM [Ki]
Delta opioid receptor 81 Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19027293 \| http://ec.europa.eu/health/documents/community-register/2013/20130225125325/anx_125325_en.pdf	Antagonist 2849	9.3 nM [Ki]
Kappa opioid receptor 115 Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19027293 \| http://ec.europa.eu/health/documents/community-register/2013/20130225125325/anx_125325_en.pdf	Partial Agonist 297	0.12 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alcoholism 20 Sources: http://ec.europa.eu/health/documents/community-register/2013/20130225125325/anx_125325_en.pdf	Primary		Approved 8583	Selincro Approved Use Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level, without physical withdrawal symptoms and who do not require immediate detoxification. Launch Date 2013

C_max

Value	Dose	Analyte	Population
24.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
57.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
155 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
177 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
274 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
647 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1320 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1876 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
314 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
16.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/	2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
109 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/	6 mg single, intravenous dose: 6 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
191 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/	12 mg single, intravenous dose: 12 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
385 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/	24 mg single, intravenous dose: 24 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
16.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8877019/	1 mg single, intravenous dose: 1 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
29.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8877019/	2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
10.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/	20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
8.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/	6 mg single, intravenous dose: 6 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/	12 mg single, intravenous dose: 12 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
8.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/	24 mg single, intravenous dose: 24 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8877019/	1 mg single, intravenous dose: 1 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
9.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8877019/	2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NALMEFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
18 mg 1 times / day steady, oral Recommended Dose: 18 mg, 1 times / day Route: oral Route: steady Dose: 18 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30829564/	unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/30829564/	Disc. AE: Psychiatric decompensation... AEs leading to discontinuation/dose reduction: Psychiatric decompensation (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/30829564/
300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3680580/	healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3680580/	Sources: https://pubmed.ncbi.nlm.nih.gov/3680580/
300 mg single, oral Highest studied dose Dose: 300 mg Route: oral Route: single Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3680580/	healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3680580/	Sources: https://pubmed.ncbi.nlm.nih.gov/3680580/
0.75 ug/kg single, intravenous Highest studied dose Dose: 0.75 ug/kg Route: intravenous Route: single Dose: 0.75 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/10754620/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10754620/	DLT: Anesthesia reversal... Dose limiting toxicities: Anesthesia reversal (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/10754620/
0.5 ug/kg single, intravenous MTD Dose: 0.5 ug/kg Route: intravenous Route: single Dose: 0.5 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/10754620/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10754620/	DLT: Anesthesia reversal... Dose limiting toxicities: Anesthesia reversal (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/10754620/
20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/	Disc. AE: Dizziness... AEs leading to discontinuation/dose reduction: Dizziness (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/
5 mg 2 times / day steady, oral Studied dose Dose: 5 mg, 2 times / day Route: oral Route: steady Dose: 5 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/	Disc. AE: Dizziness, Rash... AEs leading to discontinuation/dose reduction: Dizziness (1 patient) Rash (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/

AEs

AE	Significance	Dose	Population
Psychiatric decompensation	1 patient Disc. AE	18 mg 1 times / day steady, oral Recommended Dose: 18 mg, 1 times / day Route: oral Route: steady Dose: 18 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30829564/	unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/30829564/
Anesthesia reversal	2 patients DLT	0.75 ug/kg single, intravenous Highest studied dose Dose: 0.75 ug/kg Route: intravenous Route: single Dose: 0.75 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/10754620/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10754620/
Anesthesia reversal	3 patients DLT	0.5 ug/kg single, intravenous MTD Dose: 0.5 ug/kg Route: intravenous Route: single Dose: 0.5 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/10754620/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10754620/
Dizziness	1 patient Disc. AE	20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/
Dizziness	1 patient Disc. AE	5 mg 2 times / day steady, oral Studied dose Dose: 5 mg, 2 times / day Route: oral Route: steady Dose: 5 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/
Rash	1 patient Disc. AE	5 mg 2 times / day steady, oral Studied dose Dose: 5 mg, 2 times / day Route: oral Route: steady Dose: 5 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7847600/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inducer 440 inhibitor 2438		inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 BCRP 910 MRP2 499 OATP1B1 1079 OATP1B3 961 OCT1 620 CYP1A2 2153 CYP2A6 879 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 CYP3A4/5 296	UGT2B7 456 UGT1A3 470 UGT1A8 323 sulfotransferases 39 CYP3A4/5 91 P-gp 2052 BCRP 697 MRP2 252 OATP1B1 503 OATP1B3 435 OCT1 393	CYP1A2 832 CYP2A6 86 CYP2B6 669 CYP2C8 198 CYP2C19 329 CYP3A4/5 133

Drug as perpetrator

Target	Modality	Activity
BCRP 985	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
CYP1A2 2333	inducer 1966 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP2A6 911	inducer 1966 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP2A6 911	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP2B6 1160	inducer 1966 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP2C19 2141	inducer 1966 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP2C8 1117	inducer 1966 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP2C9 2497	inducer 1966 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP3A4/5 357	inducer 1966 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
CYP3A4/5 357	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	no
MRP2 625	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
OATP1B3 970	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
OCT1 656	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no

Drug as victim

Target	Modality	Activity
UGT1A3 470	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/product-information/selincro-epar-product-information_en.pdf#page=11 Page: 11.0	minor
UGT1A8 323	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/product-information/selincro-epar-product-information_en.pdf#page=11 Page: 11.0	minor
BCRP 697	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
MRP2 252	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
OATP1B1 503	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
OATP1B3 435	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
OCT1 393	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
P-gp 2052	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=14 Page: 14.0	no
CYP3A4/5 91	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/product-information/selincro-epar-product-information_en.pdf#page=11 Page: 11.0	yes
UGT2B7 456	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/product-information/selincro-epar-product-information_en.pdf#page=10 Page: 10.0	yes
sulfotransferases 39	substrate 4014 Sources: https://www.ema.europa.eu/en/documents/product-information/selincro-epar-product-information_en.pdf#page=11 Page: 11.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf#page=12 Page: 12.0

Sourcing

Vendor/Aggregator	ID	URL
Achemtek	0104-005955	http://www.achemtek.com/55096-26-9
AK Scientific, Inc. (AKSCI)	67672	http://www.aksci.com/item_detail.php?cat=67672
Alfa Chemistry	55096-26-9	https://www.alfa-chemistry.com/cas_55096-26-9.htm
Ambinter	Amb17618203	http://www.ambinter.com/reference/17618203
Ambinter	Amb22801010	http://www.ambinter.com/reference/22801010
ApexBio Technology	B5505	http://www.apexbt.com/nalmefene-d3.html
Aurora Fine Chemicals LLC	A17.877.204	http://online.aurorafinechemicals.com/info?ID=A17.877.204
BioChemPartner	BCP16723	http://www.biochempartner.com/55096-26-9-BCP16723
BioCrick	BCC6093	http://www.biocrick.com/Nalmefene-d3-BCC6093.html
ChemMol	49425127	http://www.chemmol.com/chemmol/49425127.html
ChemMol	99105242	http://www.chemmol.com/chemmol/99105242.html
Chemspace	CSSB00020660084	https://chem-space.com/CSSB00020660084
DC Chemicals	DC37635	http://www.dcchemicals.com//product_show-Nalmefene.html
Glentham Life Sciences	GP5746	http://www.glentham.com/products/product/GP5746/
Lab Network	LN01291034	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01291034
OChem	5964	http://www.ocheminc.com/index.php?act=psearch&pid=096N269
Sigma-Aldrich	N5770_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/n5770?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S536625	http://www.smolecule.com/products/s536625
THE BioTek	bt-276130	https://www.thebiotek.com/product/inhibitors/bt-276130

PubMed

Title	Date	PubMed
Nalmefene: intravenous safety and kinetics of a new opioid antagonist.	1986 Jan	3943269
A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.	1994 Oct	7847600
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.	1998 Mar	9686407
Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.	1999 Jan	9862779
New developments in the pharmacotherapy of alcohol dependence.	2001	11268820
Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism.	2001 Jan-Feb	11139409
Comparison of the discriminative and neuroendocrine effects of centrally penetrating kappa-opioid agonists in rhesus monkeys.	2002 Oct	12373425
Characterization of scratching responses in rats following centrally administered morphine or bombesin.	2003 Nov	14557717
A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence.	2004 Aug	15232334
Chronic administration of nalmefene leads to increased food intake and body weight gain in mice.	2004 Jul 8	15219821
Pharmacotherapy for erectile dysfunction.	2004 Sep	16422967
Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers.	2004 Sep	15365307
Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.	2004 Sep 28	15363499
Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene.	2005	16379031
Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.	2005 Dec	15956985
Unexpected placebo response in premenstrual dysphoric disorder: implication of endogenous opioids.	2005 Oct	16001107
Comorbidity issues in the pharmacological treatment of Pathological Gambling: a critical review.	2005 Oct 10	16216125
Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling.	2006 Feb	16449486
Pathological gambling: focusing on the addiction, not the activity.	2006 Feb	16449466
Pharmacologic treatments for opioid dependence: detoxification and maintenance options.	2007	18286804
Pharmacoprophylaxis of alcohol dependence: Review and update Part I: Pharmacology.	2007 Jan	20640061
Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.	2007 Jul	17451401
Plasma met-enkephalin, beta-endorphin and leu-enkephalin levels in human hepatic encephalopathy.	2007 Mar-Apr	17684846
Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers.	2007 Sep 24	17892544
Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.	2008 Feb	17473837
Imaging of opioid receptors in the central nervous system.	2008 May	18048446
The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates.	2008 Oct	18593955
The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study.	2010	21423437
Pediatric sedation: a global challenge.	2010	20981309
Pathological gambling and compulsive buying: do they fall within an obsessive-compulsive spectrum?	2010	20623922
Human exposures to immobilising agents: results of an online survey.	2010 Aug 28	20802186
Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment.	2010 Dec	22002450
[Clinical observation of the effect of nalmefene in treatment of septic shock].	2010 Jun	20594468
[Serum NT-proBNP levels in neonates with severe asphyxia and the effects of nalmefene on the NT-proBNP levels].	2010 Nov	21083993
Nalmefene for treatment of alcohol dependence.	2010 Nov	20868291
Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study.	2010 Oct	20884959
Brain imaging studies in pathological gambling.	2010 Oct	20676945
Tailoring therapeutic strategies for treating posttraumatic stress disorder symptom clusters.	2010 Sep 7	20856915
Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.	2014 Aug	24671340
Treatment of Gambling Disorders.	2014 Jun 1	24904757

Patents

Sample Use Guides

In Vivo Use Guide

How much to take - The recommended dose is one tablet on days when you think there is a risk you will drink alcohol - The maximum dose is one tablet per day. How and when to take - You should take the tablet 1-2 hours before you start drinking alcohol. - Swallow the tablet whole, do not crush or divide the tablet. - You can take Selincro (Nalmefene) with or without food. Each film-coated tablet contains 18.06 mg nalmefene (as hydrochloride dihydrate).

Route of Administration: Oral

In Vitro Use Guide

Nalmefene antagonized the bindings of [3H]-dihydromorphine, [3H]-ethylketocyclazocine and [3H]-D-ala-D-leu enkephalin with IC50's in the low nanomolar range in rat brain membranes.. At the central mu receptor, nalmefene bound with an IC50 of 1.0 nM

Name

Type

Language

JF-1

Preferred Name

English

NALMEFENE

Official Name

English

NALMEFENE [USAN]

Common Name

English

17-(Cyclopropylmethyl)-4,5?-epoxy-6-methylenemorphinan-3,14-diol

Systematic Name

English

SRD-174

Code

English

ORF-11676

Code

English

NALMEFENE [HSDB]

Common Name

English

Nalmefene [WHO-DD]

Common Name

English

ORF 11676

Code

English

ORF 1167

Code

English

JKB-121

Code

English

NALMEFENE [MI]

Common Name

English

nalmefene [INN]

Common Name

English

ORF-1167

Code

English

MORPHINAN-3,14-DIOL, 17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-6-METHYLENE-, (5.ALPHA.)-

Systematic Name

English

NALMEFENE [VANDF]

Common Name

English

SRD174

Code

English

NALMEFENE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C681